Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Accured Expenses (2023 - 2026)

Contineum Therapeutics' Change in Accured Expenses history spans 4 years, with the latest figure at -$3.5 million for Q1 2026.

  • Quarterly Change in Accured Expenses fell 23.17% to -$3.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$1.2 million through Mar 2026, down 558.66% year-over-year, with the annual reading at -$516000.0 for FY2025, 122.41% down from the prior year.
  • Change in Accured Expenses came in at -$3.5 million for Q1 2026, down from $2.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.9 million in Q4 2024 to a low of -$3.5 million in Q1 2026.
  • The 4-year median for Change in Accured Expenses is -$102000.0 (2025), against an average of -$11076.9.
  • Year-over-year, Change in Accured Expenses skyrocketed 283.05% in 2024 and then plummeted 653.16% in 2025.
  • Contineum Therapeutics' Change in Accured Expenses stood at -$1.6 million in 2023, then surged by 283.05% to $2.9 million in 2024, then fell by 28.62% to $2.1 million in 2025, then tumbled by 268.1% to -$3.5 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Change in Accured Expenses are -$3.5 million (Q1 2026), $2.1 million (Q4 2025), and $351000.0 (Q3 2025).